Matches in Wikidata for { <http://www.wikidata.org/entity/Q92016249> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92016249 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92016249 description "scientific article published on 01 March 2019" @default.
- Q92016249 description "wetenschappelijk artikel" @default.
- Q92016249 description "наукова стаття, опублікована 1 березня 2019" @default.
- Q92016249 name "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 name "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 type Item @default.
- Q92016249 label "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 label "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 prefLabel "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 prefLabel "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 P1104 Q92016249-5D7BDB98-FABC-4875-AFA4-098C15B1A656 @default.
- Q92016249 P1433 Q92016249-22C8EF18-0AFC-4A04-AD41-2F7A7EE18984 @default.
- Q92016249 P1476 Q92016249-142EEBC9-B65E-4B82-9325-137262DA478B @default.
- Q92016249 P2093 Q92016249-234600A9-3164-4F47-9C91-39BA487564CD @default.
- Q92016249 P2093 Q92016249-344EF58F-AFFF-4764-936A-F9F79F8CFE42 @default.
- Q92016249 P2093 Q92016249-66DAE5A6-0D92-46E8-9005-7F3C1DDC24A0 @default.
- Q92016249 P2093 Q92016249-B16285D1-0E60-4CA6-86F7-D9D4498C0750 @default.
- Q92016249 P2093 Q92016249-EE560B8B-CAEF-45BD-A882-744798B53214 @default.
- Q92016249 P304 Q92016249-7FF2F9EF-0BDD-4DB6-8D2E-2F77659BD235 @default.
- Q92016249 P31 Q92016249-2BE1E39A-CE44-4A76-82F3-591A84BF82EA @default.
- Q92016249 P356 Q92016249-7363E2E9-FEB2-433F-8EDD-E5541E1103AC @default.
- Q92016249 P433 Q92016249-0DB6ACEE-86C7-4DFC-B324-42BB257E575D @default.
- Q92016249 P478 Q92016249-36D20903-AADE-4BF7-8E64-71087B8D7469 @default.
- Q92016249 P50 Q92016249-53BB9005-3319-4999-AF3F-EB7EAABC23C0 @default.
- Q92016249 P577 Q92016249-56A3749D-37FA-48E9-8647-D3B12B6AF7F3 @default.
- Q92016249 P698 Q92016249-D641DF6E-322B-4617-A77A-5B065393DE72 @default.
- Q92016249 P356 APPI.AJP.2018.18111231R @default.
- Q92016249 P698 30818989 @default.
- Q92016249 P1104 "+2" @default.
- Q92016249 P1433 Q1935368 @default.
- Q92016249 P1476 "Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz" @default.
- Q92016249 P2093 "Alan F Schatzberg" @default.
- Q92016249 P2093 "Carolyn I Rodriguez" @default.
- Q92016249 P2093 "Christine Blasey" @default.
- Q92016249 P2093 "Keith Sudheimer" @default.
- Q92016249 P2093 "Nolan R Williams" @default.
- Q92016249 P304 "251-252" @default.
- Q92016249 P31 Q13442814 @default.
- Q92016249 P356 "10.1176/APPI.AJP.2018.18111231R" @default.
- Q92016249 P433 "3" @default.
- Q92016249 P478 "176" @default.
- Q92016249 P50 Q88193753 @default.
- Q92016249 P577 "2019-03-01T00:00:00Z" @default.
- Q92016249 P698 "30818989" @default.